Sai Parenterals Limited
NSE: SAIPARENTPharmaceuticals
Share price
₹493.90
-1.31% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
50
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹2,173 Cr
P/E ratio
152.4
P/B ratio
3.6
ROCE
5.3%
ROE
4.9%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 51.6% a year against a sector median of 13.1% — 38.5 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 3.2 times its growth rate, on earnings growth of 48%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Sai Parenterals Limited — this one | 48%/yr | 152.4× | ₹3.2 |
| Torrent Pharmaceuticals | 22%/yr | 79.4× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.2× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 100.5× | ₹25.1 |
| Cipla | 10%/yr | 29.4× | ₹2.9 |
| Dr Reddy's Laboratories | -4%/yr | 31.2× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 101 of 130 on returns, 2 of 127 on growth, 99 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 5.3% on capital, ahead of 22% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the 4 years of cash statements on file it made ₹83 crore of cash from the business but spent ₹328 crore on plant and equipment, ₹245 crore more than it made; the gap was from lenders and shareholders.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
5 of 9 checks clear · 56%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Reaffirmed Rs 750 crore of FY27 revenue at 17% margin; Q1 margin ran 2 points below at 14.9%.
Announced 11 Aug 2026 · Consolidated · Unaudited
Revenue
₹179 Cr
Revenue vs last year
+435.1%
Revenue vs last quarter
-9.7%
Net profit
₹8 Cr
Profit vs last year
+457.9%
Profit vs last quarter
-39.8%
Net margin
4.4%
EPS
₹1.79
Earnings call transcript · 12 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹2,173 Cr
- Prev close
- ₹493.90
- 52w High
- ₹706
- 52w Low
- ₹400
- Enterprise value
- ₹2,225 Cr
- Beta
- 0.6
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 1.0%
- PEG ratio
- 2.2
- P/E ratio
- 152.4
- P/B ratio
- 3.6
- EV / EBITDA
- 57.1
- Industry P/E
- 37.6
- ROCE
- 5.3%
- ROCE 5y average
- 12.7%
- ROE
- 4.9%
- Debt / Equity
- 1.0
- Interest coverage
- 1.6
- Dividend yield
- 0.0%
- ROE 3y average
- 9.0%
- ROE last year
- 5.0%
Annual P&L
- Annual revenue
- ₹381 Cr
- Annual profit
- ₹14 Cr
- Operating margin
- 10.0%
- Net profit margin
- 3.7%
- EBITDA margin
- 10.2%
- Sales growth 3y
- 57.8%
- Sales growth 5y
- —
- Profit growth 3y
- 48.0%
- Profit growth 5y
- —
- EPS
- ₹3.2
- Sales growth TTM
- 134.0%
- Profit growth TTM
- -1.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹179 Cr
- Profit latest quarter
- ₹8 Cr
- YoY quarterly sales growth
- 435.1%
- YoY quarterly profit growth
- 457.7%
- OPM latest quarter
- 13.2%
Balance Sheet
- Book Value
- ₹112
- Face Value
- ₹5.0
- Total debt
- ₹469 Cr
- Total cash
- ₹417 Cr
- Borrowings
- ₹469 Cr
- Reserves / Equity
- 21.3
Cash Flow
- Operating cash flow
- ₹93 Cr
- Free cash flow
- -₹184 Cr
- FCF yield
- -9.3%
- Net cash flow
- ₹415 Cr
Shareholding
- Promoter holding
- 51.2%
- FII holding
- 4.0%
- DII holding
- 8.5%
- Public holding
- 36.3%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,758.25 | 33.3 | 4,21,863 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,425.00 | 84.0 | 2,50,204 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,631.20 | 79.0 | 1,76,156 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,115.60 | 22.9 | 1,11,282 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,019.55 | 99.8 | 1,09,119 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,301.20 | 29.4 | 1,05,120 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,393.20 | 46.3 | 98,850 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Sai Parenteral's | 501.10 | 106.6 | 2,214 | 0.00 | 7.9 | 457.8 | 178.7 | 435.1 | 5.3 |
| Median | 414.00 | 34.1 | 2,123 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 33 | 87 | 96 | 198 | 179 |
| Expenses | 29 | 100 | 172 | 155 | |
| Material Cost | 59 | 114 | 116 | ||
| Change in Inventories | 2.57 | 10 | -9.90 | ||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | ||
| Employee Cost | 10 | 12 | 12 | ||
| Other Expenses | 28 | 35 | 37 | ||
| Operating Profit | 4.74 | -3.56 | 26 | 24 | |
| OPM % | 14 | 19 | -3.70 | 13 | 13 |
| Other Income | 1.17 | 3.13 | 2.88 | 3.74 | |
| Exceptional items (within Other Income) | 0 | 0 | 0 | ||
| Interest | 2.46 | 5.41 | 8.40 | 9.36 | |
| Depreciation | 1.45 | 5.79 | 8.18 | 8.11 | |
| Profit before tax | 2 | -12 | 12 | 9.79 | |
| Tax % | 30 | -43 | -6.13 | 19 | |
| Net Profit | 1.42 | -6.66 | 13 | 7.92 | |
| EPS in Rs | 0.52 | -1.80 | 2.98 | 1.79 | |
| Diluted EPS in Rs | -2.22 | 4.02 | 1.79 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 97 | 154 | 163 | 381 |
| Expenses | 78 | 122 | 124 | 342 |
| Material Cost | 238 | |||
| Change in Inventories | 4.11 | |||
| Purchases of Stock-in-Trade | 0 | |||
| Employee Cost | 29 | |||
| Other Expenses | 71 | |||
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19 | 21 | 24 | 10 |
| Other Income | 0 | 1 | 1 | 9 |
| Exceptional items (within Other Income) | 0 | |||
| Interest | 6 | 11 | 12 | 19 |
| Depreciation | 6 | 9 | 8.20 | 17 |
| Profit before tax | 7 | 13 | 20 | 12 |
| Tax % | 40 | 33 | 28 | -20 |
| Net Profit | 4 | 8 | 14 | 14 |
| EPS in Rs | 6.13 | 6.36 | 5.43 | 3.23 |
| Diluted EPS in Rs | 4.36 | |||
| Dividend Payout % | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- 58%
- TTM
- 134%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 48%
- TTM
- -1%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- 9%
- Last year
- 5%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings | 69 | 119 | 94 | 469 |
| Other Liabilities | 34 | 75 | 85 | 465 |
| Minority Interest | 4.35 | |||
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1,424 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from Operating Activity | -13 | -30 | 33 | 93 |
| Cash from Investing Activity | -19 | -46 | 0 | -274 |
| Cash from Financing Activity | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 256 | 208 |
| Working Capital Days | 19 | 72 | 79 | -161 |
| ROCE % | 16 | 17 | 5 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
In the last 1 year the price has not moved enough to draw bricks. Try a longer range.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
52.00inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Sai Parenterals Limited. Open one to see why it matters.
26 Aug, 18:05 IST · Company event · medium impact
Sai Parenterals Limited has won a new order or contract
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Active pharmaceutical ingredients (APIs)
- Excipients
- Intermediates
- Packing materials
Makes products for
- Noumed Pharmaceuticals Pty Limited
Sells to
- Abbott India Limited · pharmaceutical formulations / parenteral products (CDMO)
- GlaxoSmithKline Pharmaceuticals Limited · pharmaceutical formulations / parenteral products (CDMO)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE0H9F01037
Plants
- Sai Parenterals Revat Unit
- Sai Parenterals Unit I
- Sai Parenterals Unit II
- Sai Parenterals Unit III
- Sai Parenterals Unit IV
News impact
Big market events that reach Sai Parenterals Limited, and how the effect spreads.
12 Sept, 04:23 IST · Market event · medium impact
Granules India promoter sells 1.72 crore shares worth Rs 1,500 crore; Goldman Sachs, BNP Paribas among buyers
Granules' owners sold Rs 1,500 crore of shares, which usually pushes the price down for a while — but big names like Goldman Sachs bought, which suggests the company itself is fine.
Who it hits first
- Granules faces 2-4% technical pressure from Rs 1,500 cr of new free float
- Quality buyers (Goldman, BNP) validate the business and likely mark a near-term floor
- Pharma peers see no fundamental change — ranked names are sentiment-only
Who may gain
- Goldman Sachs, BNP Paribas and other block buyers who accumulated at a discount
- Granules' public float and liquidity improve post-deal
Along the supply chain
Downstream
Formulation customers and distributors are unaffected; pricing and contracts continue as before.
Upstream
No supply-chain link — API suppliers and job-workers see no order change from a share sale.
Where demand moves
Business
No business demand shifts — this is a pure ownership transfer; Granules' API and formulations orders are untouched.
Capital
Promoter supply meets institutional demand at a small discount; some weak holders exit on the news while quality funds accumulate — net neutral to mildly positive for the register.
How it spreads across sectors
Healthcare
neutral — single-stock block with quality buyers; no sector read-through
When it plays out
Immediate
Granules dips 2-4% on supply overhang; peers flat
Medium term
Non-event for earnings — price rejoins fundamentals within a quarter
Short term
Block gets absorbed in 1-2 weeks; quality-holder register supports stability
28 Jun, 02:05 IST · Market event · medium impact
AbbVie (ABBV) to Acquire Apogee Therapeutics
Who it hits first
- AbbVie (ABBV) and Apogee Therapeutics are US-listed; neither is in the Indian knowledge graph — zero direct impact on Indian listed companies.
Who may gain
- Sentiment-level read-across to Indian biologics/biosimilar innovators (immunology-biologics theme stays in focus) and, as a diffuse long-term theme, the CDMO/CRO category as global pharma deploys M&A capital.
Along the supply chain
Downstream
No downstream supply-chain link — a US biotech acquisition does not change product flows to or from any Indian listed company.
Upstream
No upstream supply-chain link — AbbVie and Apogee are US entities; no Indian listed company supplies APIs, intermediates or services into this specific transaction.
Where demand moves
Business
No direct business-demand flow — the AbbVie-Apogee deal neither creates nor destroys orders for any Indian company. Any effect (global pharma capital deployment lifting long-term outsourcing demand for Indian CDMO/CRO players) is a diffuse second-order theme, not a measurable order shift.
Capital
Capital-flow read-across only — a global immunology M&A reinforces a positive innovator-pharma narrative that can support Indian pharma valuations at the margin; the effect is sentiment-level and strongest for biologics/biosimilar names such as Biocon.
How it spreads across sectors
Healthcare
negligible — hospital operators have no business channel to a US drug-developer acquisition
Pharma
mild positive sentiment from the global pharma M&A consolidation/innovation theme
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 2 Jul 2026 | HRTI PRIVATE LIMITED | SELL | 2,26,834 | ₹637.95 |
| 2 Jul 2026 | HRTI PRIVATE LIMITED | BUY | 1,05,392 | ₹639.68 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-2619 Aug 2026
- Earnings call12 Aug 2026
- Results presentation30 Jun 2026
- Earnings call27 May 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.